Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074802 · ClinicalTrials.gov registry record · Phase 3
Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
A Phase 3 study of Social Anxiety Disorder, sponsored by Temple University.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT00074802: Completed Phase 3 study of Social Anxiety Disorder, sponsored by Temple University.
NCT00074802 is a Phase 3 study of Social Anxiety Disorder that has completed, run by Temple University. The registered enrollment target is 150 participants, roughly in line with the 155-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00074802, a Phase 3 study of Social Anxiety Disorder, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will examine whether the addition of cognitive behavioral therapy can improve the efficacy of the medication paroxetine (Paxil®) in treating individuals with social anxiety disorder. Patients with social anxiety disorder will undergo a 12-week open trial with paroxetine. Those who complete the open trial having achieved only partial response will be randomized to receive cognitive behavioral therapy (CBT) in addition to paroxetine or to continue on paroxetine alone for an additional 16 weeks.
Primary Outcome
The LSAS is a 24-item clinician-administered measure, which provides 0-3 ratings for anxiety and avoidance of social and performance situations. Anxiety and avoidance ratings are summed across items, yielding a range of scores from 0-144, with higher scores representing greater severity of social anxiety symptoms. We examined amount of change from week 12 to week 28 as the primary outcome. Change was calculated as Week 12 score minus Week 28 score, so a positive score equals greater positive cha
Conditions Studied
Interventions
- DRUG Paroxetine
- BEHAVIORAL Cognitive behavioral therapy (CBT)
Study Locations (2)
New York
- New York State Psychiatric Institute Anxiety Disorders Clinic - New York
Pennsylvania
- Adult Anxiety Clinic of Temple University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-12 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
What the finished NCT00074802 record still lists
NCT00074802 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 155-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target.
The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Paroxetine is the first listed.
NCT00074802 reports a single indexed study location in New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00074802 about?
NCT00074802 is a clinical study titled "Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder". This study will examine whether the addition of cognitive behavioral therapy can improve the efficacy of the medication paroxetine (Paxil®) in treating individuals with social anxiety disorder. Patients with social anxiety disorder will undergo a 12-week open trial with paroxetine. Those who complet...
What is the current status of trial NCT00074802?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2003-12. Estimated completion is 2008-05.
What conditions does trial NCT00074802 study?
This clinical trial studies the following conditions: Social Anxiety Disorder.
What interventions are being tested in trial NCT00074802?
The interventions under investigation include: Paroxetine (DRUG), Cognitive behavioral therapy (CBT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00074802?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00074802 being conducted?
This trial has 2 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00074802's enrollment target sits among peer trials
150 13th of 32 higher than 19 of 32 other Social Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Social Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
RECRUITING · Phase 3
-
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
COMPLETED · Phase 3
-
Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety
COMPLETED · Phase 3
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia